Ansa Biotechnologies

Ansa Biotechnologies is a provider of DNA synthesis technology using enzymatic methods. The company's technology is based on polymerase-nucleotide conjugates that can extend a DNA molecule by one building block at a time, offering a next-generation alternative to traditional chemical DNA synthesis. This enzymatic approach enables longer, more accurate DNA sequences with reduced environmental impact. Ansa's technology serves applications in synthetic biology, drug discovery, diagnostics, and genetic engineering. Founded in 2017 and headquartered in Berkeley, California, Ansa Biotechnologies has raised approximately $176.7 million at the Series B stage from investors including Northpond Ventures, RA Capital Management, Mubadala, Fifty Years, Horizons Ventures, Altitude Life Science Ventures, PEAK6, Carbon/Silicon, Codon Capital, Cerberus Capital Management, America's Seed Fund, and Humboldt Fund. The company employs 76 people.